Referenser Njur- och urinvägssjukdomar

  1. Njursvikt, kroniskt, AKO Skåne-riktlinje för primärvården, 2021
  2. Nationellt vårdprogram för kronisk njursjukdom, NPO njur-och urinvägssjukdomar, 2021
  3. Urininkontinens hos kvinnor, AKO Skåne-riktlinje för primärvården, 2021
  4. Benign prostatahyperplasi, AKO Skåne-riktlinje för primärvården, 2021
  5. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting, lin, 2020
  6. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis , Chapple et al. Eur Urol 2008;54:543
  7. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder, Novara et al. Eur Urol 2008; 54:740
  8. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. Kaplan et al. BJU Int 2011; 107:1432
  9. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Meek et al. Dig Dis Sci 2011; 56:7
  10. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? Paquette et al. J Am Geriatr Soc 2011; 59:1332
  11. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study, 2020
  12. Gray SL, Anderson ML, Dublin S et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175: 401–7
  13. Richardson K, Fox C, Maidment I et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018; 361: k1315
  14. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019; 179: 1084
  15. Nokturi och nattlig polyuria, AKO Skåne-riktlinje för primärvården, 2021
  16. Erektil dysfunktion, AKO Skåne-riktlinje för primärvården, 2021
  17. Behandling av erektil dysfunktion - från piller till implantat, Uvelius et al. Läkartidningen 8/2020
  18. Benign prostatahyperplasi, AKO Skåne-riktlinje för primärvården, 2021
  19. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Roehrborn et al. Urology 1999; 53:581
  20. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Porst et al. Urology 2013; 82:667
  21. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms sug- gestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. Giuliano et al. J Sex Med 2013; 10:857
  22. Prostatacancer, AKO Skåne-riktlinje för primärvården, 2021
  23. Standardiserat vårdförlopp prostatacancer, Helena Brändström, nationell samordnare vårdprogram, RCC Uppsala Örebro, 2020
  24. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?, Perachino et al. BJU Int 2010 ;105 :648
  25. Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy Morote et al. J Urol 2007;178:1290
  26. Lenhard et al. Data on file. Sandoz A/S Danmark
  27. Anticholinergic drugs and risk of dementia: Time for action?. Pharmacol Res Perspect. Bell B, Avery A, Bishara D, Coupland C, Ashcroft D, Orrell M, 2021;9:e00793. 

Fick du hjälp av informationen på sidan?

Tack för din hjälp att förbättra webbplatsen, dina synpunkter har skickats till webbredaktionen.